Russian Parliament mulls restrictions on US drugmakers

25 April 2018

The Russian national Parliament (State Duma) plans to consider the possibility of introducing a ban on the imports of drugs from the USA and some European Union states to Russia at the beginning of the current year, according to Duma press-service.

The introduction of ban will be a response to the latest package of sanctions, imposed on Russia by the US government and which have led to serious problems for some Russian businessmen, reports The Pharma Letter’s local correspondent.

According to Russian pharmaceutical analytics firm DSM Group, the share of imported drugs on the Russian market in 2017 exceeded 70%. The number of imported drugs for which analogues are produced within the country is not available.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK